A preclinical randomized controlled multi-centre trial of anti-interleukin-17A treatment for acute ischaemic stroke

Abstract Multiple consensus statements have called for preclinical randomized controlled trials to improve translation in stroke research. We investigated the efficacy of an interleukin-17A neutralizing antibody in a multi-centre preclinical randomized controlled trial using a murine ischaemia reperfusion stroke model. Twelve-week-old male C57BL/6 mice were subjected to 45 min of transient middle cerebral artery occlusion in four centres. Mice were randomly assigned (1:1) to receive either an anti-interleukin-17A (500 µg) or isotype antibody (500 µg) intravenously 1 h after reperfusion. The primary endpoint was infarct volume measured by magnetic resonance imaging three days after transient middle cerebral artery occlusion. Secondary analysis included mortality, neurological score, neutrophil infiltration and the impact of the gut microbiome on treatment effects. Out of 136 mice, 109 mice were included in the analysis of the primary endpoint. Mixed model analysis revealed that interleukin-17A neutralization significantly reduced infarct sizes (anti-interleukin-17A: 61.77 ± 31.04 mm3; IgG control: 75.66 ± 34.79 mm3; P = 0.01). Secondary outcome measures showed a decrease in mortality (hazard ratio = 3.43, 95% confidence interval = 1.157–10.18; P = 0.04) and neutrophil invasion into ischaemic cortices (anti-interleukin-17A: 7222 ± 6108 cells; IgG control: 28 153 ± 23 206 cells; P < 0.01). There was no difference in Bederson score. The analysis of the gut microbiome showed significant heterogeneity between centres (R = 0.78, P < 0.001, n = 40). Taken together, neutralization of interleukin-17A in a therapeutic time window resulted in a significant reduction of infarct sizes and mortality compared with isotype control. It suggests interleukin-17A neutralization as a potential therapeutic target in stroke.

[1]  M. Endres,et al.  Immune Pathways in Etiology, Acute Phase, and Chronic Sequelae of Ischemic Stroke , 2022, Circulation research.

[2]  Timothy M. Errington,et al.  Investigating the replicability of preclinical cancer biology , 2021, eLife.

[3]  Sang Hoon Lee,et al.  IL-23/IL-17A/TRPV1 axis produces mechanical pain via macrophage-sensory neuron crosstalk in female mice , 2021, Neuron.

[4]  Timothy M. Errington,et al.  Challenges for assessing replicability in preclinical cancer biology , 2021, eLife.

[5]  J. Kipnis,et al.  Neuromodulation by the immune system: a focus on cytokines , 2021, Nature Reviews Immunology.

[6]  Jasmin Herz,et al.  Functional characterization of the dural sinuses as a neuroimmune interface , 2021, Cell.

[7]  U. Dirnagl,et al.  Improving preclinical studies through replications , 2021 .

[8]  Junfa Li,et al.  IL-17A Neutralization Improves the Neurological Outcome of Mice With Ischemic Stroke and Inhibits Caspase-12-Dependent Apoptosis , 2020, Frontiers in Aging Neuroscience.

[9]  M. Elkind,et al.  Natalizumab in acute ischemic stroke (ACTION II) , 2020, Neurology.

[10]  C. Iadecola,et al.  Immune responses to stroke: mechanisms, modulation, and therapeutic potential. , 2020, The Journal of clinical investigation.

[11]  L. McCullough,et al.  Gut Microbiota–Derived Short-Chain Fatty Acids Promote Poststroke Recovery in Aged Mice , 2020, Circulation research.

[12]  J. Wellmann,et al.  Why Most Acute Stroke Studies Are Positive in Animals but Not in Patients: A Systematic Comparison of Preclinical, Early Phase, and Phase 3 Clinical Trials of Neuroprotective Agents , 2019, Annals of neurology.

[13]  S. Gaffen,et al.  IL-17 receptor–based signaling and implications for disease , 2019, Nature Immunology.

[14]  Francesco Asnicar,et al.  Author Correction: Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2 , 2019, Nature Biotechnology.

[15]  A. Stensballe,et al.  Topical Administration of a Soluble TNF Inhibitor Reduces Infarct Volume After Focal Cerebral Ischemia in Mice , 2019, Front. Neurosci..

[16]  Monya Baker,et al.  Reporting animal research: Explanation and Elaboration for the ARRIVE guidelines 2019 , 2019, bioRxiv.

[17]  D. Odom,et al.  IL‐7‐dependent compositional changes within the γδ T cell pool in lymph nodes during ageing lead to an unbalanced anti‐tumour response , 2019, EMBO reports.

[18]  C. Justicia,et al.  Location of Neutrophils in Different Compartments of the Damaged Mouse Brain After Severe Ischemia/Reperfusion. , 2019, Stroke.

[19]  Fares Alahdab,et al.  Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2019, The Lancet Neurology.

[20]  Yan He,et al.  Stroke Dysbiosis Index (SDI) in Gut Microbiome Are Associated With Brain Injury and Prognosis of Stroke , 2019, Front. Neurol..

[21]  L. Burkhardt,et al.  Changes in the composition of the upper respiratory tract microbial community in granulomatosis with polyangiitis. , 2019, Journal of autoimmunity.

[22]  Betty Y. S. Kim,et al.  How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation , 2018, Nature Biomedical Engineering.

[23]  C. Gerloff,et al.  MRI‐Guided Thrombolysis for Stroke with Unknown Time of Onset , 2018, The New England journal of medicine.

[24]  C. Gerloff,et al.  IL-23 (Interleukin-23)–Producing Conventional Dendritic Cells Control the Detrimental IL-17 (Interleukin-17) Response in Stroke , 2018, Stroke.

[25]  Benjamin S Braun,et al.  A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies. , 2017, Cancer research.

[26]  Ramnik J. Xavier,et al.  Human genetic variation and the gut microbiome in disease , 2017, Nature Reviews Genetics.

[27]  M. Veldhoen.  Interleukin 17 is a chief orchestrator of immunity , 2017, Nature Immunology.

[28]  Á. Chamorro,et al.  Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation , 2016, The Lancet Neurology.

[29]  M. Baker.  1,500 scientists lift the lid on reproducibility , 2016, Nature.

[30]  Arthur Liesz,et al.  The next step in translational research: lessons learned from the first preclinical randomized controlled trial , 2016, Journal of neurochemistry.

[31]  B. Kristensen,et al.  Cell therapy centered on IL-1Ra is neuroprotective in experimental stroke , 2016, Acta Neuropathologica.

[32]  N. Rothwell,et al.  A cross-laboratory preclinical study on the effectiveness of interleukin-1 receptor antagonist in stroke , 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[33]  N. Plesnila,et al.  Results of a preclinical randomized controlled multicenter trial (pRCT): Anti-CD49d treatment for acute brain ischemia , 2015, Science Translational Medicine.

[34]  Hester F. Lingsma,et al.  A randomized trial of intraarterial treatment for acute ischemic stroke. , 2015, The New England journal of medicine.

[35]  Á. Chamorro,et al.  Neutrophil recruitment to the brain in mouse and human ischemic stroke , 2015, Acta Neuropathologica.

[36]  M. Endres,et al.  Found in translation: preclinical stroke research predicts human pathophysiology, clinical phenotypes, and therapeutic outcomes. , 2014, Stroke.

[37]  S. Perrin.  Preclinical research: Make mouse studies work , 2014, Nature.

[38]  Ulrich Dirnagl,et al.  A Concerted Appeal for International Cooperation in Preclinical Stroke Research , 2013, Stroke.

[39]  C. Gerloff,et al.  Neutralization of the IL-17 axis diminishes neutrophil invasion and protects from ischemic stroke. , 2012, Blood.

[40]  S. Lazic,et al.  A call for transparent reporting to optimize the predictive value of preclinical research , 2012, Nature.

[41]  Johannes E. Schindelin,et al.  Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.

[42]  Ulrich Dirnagl,et al.  International, Multicenter Randomized Preclinical Trials in Translational Stroke Research: It's Time to Act , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[43]  O. Steward,et al.  Replication and reproducibility in spinal cord injury research , 2012, Experimental Neurology.

[44]  D. Moher,et al.  CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials , 2010, BMJ : British Medical Journal.

[45]  D. Moher,et al.  CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials , 2010, BMJ : British Medical Journal.

[46]  M. Macleod,et al.  Emulating Multicentre Clinical Stroke Trials: A New Paradigm for Studying Novel Interventions in Experimental Models of Stroke , 2009, International journal of stroke : official journal of the International Stroke Society.

[47]  Dan R. Littman,et al.  Induction of Intestinal Th17 Cells by Segmented Filamentous Bacteria , 2009, Cell.

[48]  Christian Gerloff,et al.  Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. , 2009, Stroke.

[49]  G. Donnan,et al.  1,026 Experimental treatments in acute stroke , 2006, Annals of neurology.

[50]  G. Bachmann,et al.  Noninvasive Quantification of Brain Edema and the Space-Occupying Effect in Rat Stroke Models Using Magnetic Resonance Imaging , 2004, Stroke.

[51]  Koroshetz Wj,et al.  Tissue plasminogen activator for acute ischemic stroke. , 1996, The New England journal of medicine.

[52]  R O Weller,et al.  Interrelationships of the pia mater and the perivascular (Virchow-Robin) spaces in the human cerebrum. , 1990, Journal of anatomy.